Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

Medicine and Dentistry

• Patient 100%
• Lung Cancer 100%
• Nivolumab 100%
• Diabetes Mellitus 100%
• Autoimmune Diabetes 100%
• Diabetic Ketoacidosis 100%
• Immune Checkpoint Inhibitor 66%
• Therapeutic Procedure 58%
• Diabetes 58%
• Autoantibody 41%
• Combination Therapy 25%
• Non Small Cell Lung Cancer 25%
• Immune-Related Adverse Events 25%
• Development 16%
• Cancer 16%
• Woman 8%
• Clinical Trial 8%
• Mortality 8%
• Incidence 8%
• Adult 8%
• Inpatient 8%
• Disease Exacerbation 8%
• Chemotherapy 8%
• Clinician 8%
• Family History 8%
• Case Report 8%
• Cancer Recurrence 8%
• Morbidity 8%
• Recognition 8%
• Biological Marker 8%
• Blood Sampling 8%
• Hyperglycemia 8%
• Case Presentation 8%
• Insulin Dependent Diabetes Mellitus 8%
• Insulin Infusion 8%
• Emergency 8%
• Side Effect 8%
• Cancer Immunotherapy 8%
• Human Leukocyte Antigen 8%
• Chemoradiation Therapy 8%